Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026)
Cogent Biosciences (COGT) recorded quarterly Return on Capital Employed of 41.98% in Q1 2026, up 22.19% quarter-over-quarter from 53.96% in Q4 2025, and up 7047.0% on a YoY basis from 0.59% in Q1 2025.
Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026) Analysis & Trends
Cogent Biosciences' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 41.98% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7047.0% year-over-year to 41.98%; the TTM figure through Mar 2026 stood at 41.98% (up 7047.0% YoY), while the FY2025 annual figure was 58.61%, up 4554.0% from the prior year.
- Return on Capital Employed was 41.98% for Q1 2026 at Cogent Biosciences, up from 53.96% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.89% in Q3 2022 to a low of 135.66% in Q2 2025.
- Historically, Return on Capital Employed has averaged 68.55% across 5 years, with a median of 59.22% in 2024.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 7644 bps in 2025, then jumped 7047 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 51.1% in 2022, then sank by 37 bps to 70.25% in 2023, then plunged by 31 bps to 91.9% in 2024, then surged by 41 bps to 53.96% in 2025, then grew by 22 bps to 41.98% in 2026.
- The last three Return on Capital Employed figures came in at 41.98% (Q1 2026), 53.96% (Q4 2025), and 106.76% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - | -41.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.98% |
| Dec 31, 2025 | -53.96% |
| Sep 30, 2025 | -106.76% |
| Jun 30, 2025 | -135.66% |
| Mar 31, 2025 | -112.45% |
| Dec 31, 2024 | -91.90% |
| Sep 30, 2024 | -73.58% |
| Jun 30, 2024 | -59.22% |
| Mar 31, 2024 | -63.48% |
| Dec 31, 2023 | -70.25% |
| Sep 30, 2023 | -57.09% |
| Jun 30, 2023 | -56.58% |
| Mar 31, 2023 | -61.20% |
| Dec 31, 2022 | -51.10% |
| Sep 30, 2022 | -39.89% |
| Jun 30, 2022 | -43.56% |
| Mar 31, 2022 | -46.71% |
| Dec 31, 2021 | -36.56% |
| Sep 30, 2021 | -29.90% |
| Jun 30, 2021 | -45.01% |